Identification of two tofacitinib subpopulations with different relative risk versus TNF inhibitors: an analysis of the open label, randomised controlled study ORAL Surveillance
Conclusions
This posthoc analysis of ORAL Surveillance identified two tofacitinib subpopulations with different relative risk versus TNFi. High risk was confined to patients defined by distinct risk factors age ≥65 years or smoking, and these differentiating risk factors accounted for the excess risk observed with tofacitinib versus TNFi. These findings can guide individualised benefit/risk assessment and clinical decision-making on treatment with tofacitinib.
Trial registration numbers
NCT02092467, NCT01262118, NCT01484561, NCT00147498, NCT00413660, NCT00550446, NCT00603512, NCT00687193, NCT01164579, NCT00976599, NCT01059864, NCT01359150, NCT02147587, NCT00960440, NCT00847613, NCT00814307, NCT00856544, NCT00853385, NCT01039688, NCT02281552, NCT02187055, NCT02831855, NCT00413699, NCT00661661, NCT00787202, NCT01465763, NCT01458951, NCT01458574, NCT01470612, NCT01877668, NCT01882439, NCT01976364.
Source: Annals of the Rheumatic Diseases - Category: Rheumatology Authors: Kristensen, L. E., Danese, S., Yndestad, A., Wang, C., Nagy, E., Modesto, I., Rivas, J., Benda, B. Tags: Open access, ARD Lay summaries, ARD, Rheumatoid arthritis Source Type: research
More News: Arthritis | Cancer | Cancer & Oncology | Cardiology | Cardiovascular | Clinical Trials | Heart | Heart Attack | Inflammatory Bowel Disease | Melanoma | Nonmelanoma Skin Cancer | Oral Cancer | Psoriatic Arthritis | Rheumatoid Arthritis | Rheumatology | Skin | Skin Cancer | Smokers | Study | Thrombosis | Ulcerative Colitis